Regeneron Announces 400 New Jobs in Limerick

August 27, 2020

Limerick, Ireland (August 27, 2020) -- Regeneron Pharmaceuticals, Inc., (NASDAQ: REGN) a leading, science-driven biopharmaceutical company, today announced that it will add more than 400 new jobs, bringing total headcount to over 1,400 at its Industrial Operations and Product Supply (IOPS) campus in the Limerick area.

The new jobs will support the production of Regeneron’s existing life-changing medicines. The company is maximizing manufacturing capacity at its New York facility for REGN-COV2, Regeneron’s investigational two-antibody combination being developed for the potential treatment and prevention of COVID-19 infection.

The creation of more than 400 new jobs is part of Regeneron’s long-term commitment to Ireland and the Limerick community. Since 2014, Regeneron has invested over $1 billion to build the largest bulk biologics production facility in the country, with over 1,000 employees, more than 300 contingent workers and close to 500 construction personnel currently working on site. Recruitment is underway to hire full-time, high-end specialist jobs in commercial manufacturing, process sciences, quality assurance/control, supply chain and various support functions for scientists, chemists and technicians.

Dan Van Plew, Executive Vice President & General Manager of IOPS at Regeneron said, “As this pandemic hit, we needed to quickly change how we do things and where we make our products. In order to make space in our New York facilities to accommodate our COVID-19 efforts, we needed to ramp-up capacity here in Limerick. Despite ramping up commercial production sooner than planned, my team hasn’t missed a beat. You can only perform like this if you have good people, and Ireland has lots of good people, so we are excited to be hiring 400 more.”

Niall O'Leary, Vice President & Site Head, IOPS Limerick said, “Just six years ago, we hired our first employee in Limerick. Today, we have more than 1,000 full-time employees at our Limerick campus and with this latest announcement we are adding an additional 400 people to our world-class team. This demonstrates not only Regeneron’s incredibly strong pipeline but our commitment to Ireland and the Mid-West region. I am very proud of what our team has achieved and continue to be impressed with the calibre of talent here.”

An Taoiseach Micheál Martin said, “This significant jobs announcement by Regeneron is a further vote of confidence in the skills and talent of our workforce and provides a welcome boost to our economy. Ireland continues to resonate with leading global companies for investment. The government’s mission over the coming months and years is to rebuild our society and economy in the post-COVID world. We need to get people back to work and to protect and create sustainable jobs. This announcement is an important and welcome step in that journey.”

An Tánaiste and Minister for Enterprise, Trade and Employment Leo Varadkar said, “Since choosing Limerick as their home, Regeneron has gone from strength to strength. Today’s announcement comes as a welcome boost for Ireland and the Mid-West at a very tough time. It’s a big vote of confidence in the future of the Irish economy. It will create an additional 400 well-paid jobs, bringing their total workforce here to 1,400. Ireland has the skills and talent to make it the perfect country for companies creating the jobs of the future.”

Mary Buckley, Executive Director, IDA Ireland said, “The addition of 400 highly skilled roles by Regeneron at its Limerick campus is a huge boost for Ireland and the Mid-West region. The company has expanded rapidly since it first chose to locate in Limerick. This significant job announcement by Regeneron in a regional location is very welcome and points to Ireland’s reputation as a global location of excellence for biopharmaceuticals. I wish the team continued success as they welcome 400 new colleagues to the site in the coming months.”

Visit www.regeneron.ie to learn more and see a current list of job openings in Ireland.

About Regeneron Limerick

Regeneron’s 64,000 square-metre, state-of-the-art Industrial Operations and Product Supply (IOPS) facility on approximately 20 hectares in the Raheen Business Park is the largest-scale bulk biologics production facility in Ireland. The facility became operational in 2015 and now employs more than 1,000 people.

IOPS is responsible for the production, packaging, labeling and supply of Regeneron medicines. IOPS manufactures a broad range of biopharmaceuticals for patients worldwide, including therapeutic proteins approved for marketing.

Recruitment is underway to bring on additional high-end specialist jobs in commercial manufacturing, process sciences, quality assurance/control and various support functions for scientists, chemists and technicians.

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the
Forward-Looking Statements and Use of Digital Media

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron’s business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron’s and its collaborators’ ability to continue to conduct research and clinical programs, Regeneron’s ability to manage its supply chain, net product sales of products marketed by Regeneron and/or its collaborators, and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron’s products and product candidates and research and clinical programs now underway or planned, including without limitation REGN-COV2; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s product candidates, such as REGN-COV2; and the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-Q for the quarterly period ended June 30, 2020. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

Contacts:

Media Relations
Edelman T: 01 5921330| E: regeneronDUB@edelman.com
Regeneron: media@regeneron.com